Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine, Docetaxel, and Thalidomide in Metastatic Prostate Cancer
NCT00083005Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in prostate cancer (PCa), sponsored by National Institutes of Health. Primary endpoints: Prostate-specific antigen response and Toxicity profile. Started Mar 2004; status: completed.
02
Drugs
thalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00083005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083005.